癌症肿瘤分析市场规模、份额、成长分析、按癌症类型、按生物标记类型、按技术、按方法、按应用、按地区 - 行业预测，2025 年至 2032 年

癌症肿瘤分析市场预计将从 2024 年的 134.4 亿美元成长到 2032 年的 312 亿美元，预测期内（2025-2032 年）的复合年增长率为 11.1%。

癌症发生率的上升以及生物标记在肿瘤分析中的应用增多，增强了全球癌症检测和治疗市场的发展。不断增加的研究资金和技术进步正在推动癌症和肿瘤分析领域的发展。此外，个人化医疗和照护现场诊断的趋势预计将在未来几年为市场参与企业创造巨大的商机。 COVID-19 疫情最初扰乱了癌症检测和诊断，但整体市场仍保持弹性。癌症/肿瘤分析领域（包括基因组学、蛋白质组学、表观遗传学和代谢体学）预计在预测期内将实现增长，其中基因组学预计最高复合年增长率为 19.7%，推动揭示与癌症復原力和进展相关的基因异常的创新。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

癌症肿瘤分析市场规模（按癌症类型）

• 市场概况
• 乳癌
• 肺癌
• 大肠直肠癌
• 摄护腺癌
• 黑色素瘤
• 其他癌症

癌症肿瘤分析市场规模（依生物标记类型）

• 市场概况
• 基因生物标誌物
• 蛋白质生物标记

癌症肿瘤分析市场规模（按技术）

• 市场概况
• 免疫检测
• 次世代定序
• 聚合酵素链锁反应
• 质谱分析
• 原位杂交
• 微阵列
• 其他的

癌症肿瘤分析市场规模（依方法）

• 市场概况
• 基因组学
• 蛋白质体学
• 代谢体学
• 表观遗传学

癌症肿瘤分析市场规模（按应用）

• 市场概况
• 调查
• 生物标记发现
• 个人化医疗
• 临床应用
• 诊断
• 预言
• 筛检
• 治疗和监测

癌症肿瘤分析市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Illumina, Inc.（USA）
• QIAGEN NV（Netherlands）
• NeoGenomics, Inc.（USA）
• Thermo Fisher Scientific（USA）
• Roche Diagnostics（Switzerland）
• Guardant Health, Inc.（USA）
• Foundation Medicine, Inc.（USA）
• Sysmex Corporation（Japan）
• Becton, Dickinson and Company（BD）（USA）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Merck & Co., Inc.（USA）
• Pfizer Inc.（USA）
• Novartis AG（Switzerland）
• AstraZeneca（UK）
• Bristol-Myers Squibb Company（USA）
• Johnson & Johnson（USA）
• Danaher Corporation（USA）
• Abbott Laboratories（USA）

结论和建议

Global Cancer Tumor Profiling Market size was valued at USD 12.1 billion in 2023 and is poised to grow from USD 13.44 billion in 2024 to USD 31.2 billion by 2032, growing at a CAGR of 11.1% during the forecast period (2025-2032).

The global cancer detection and treatment market is bolstered by the rising prevalence of cancer and the increasing utilization of biomarkers in tumor profiling. Enhanced research funding and technological advancements are fueling growth in the cancer and tumor profiling sectors. Furthermore, the trend towards personalized medicine and point-of-care diagnostics is anticipated to create substantial opportunities for market participants in the coming years. While the COVID-19 pandemic initially disrupted cancer testing and diagnosis, the overall market remained resilient. During the forecast period, cancer/tumor profiling segments encompassing genomics, proteomics, epigenetics, and metabolomics are expected to thrive, with genomics projected to achieve the highest CAGR of 19.7%, driving innovations in understanding gene abnormalities connected to cancer resilience and progression.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Tumor Profiling market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Tumor Profiling Market Segments Analysis

Global Cancer Tumor Profiling Market is segmented by Cancer type, Biomarker type, Technology, Technique, Application and region. Based on Cancer type, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer. Based on Biomarker type, the market is segmented into Genomic Biomarker and Protein Biomarker. Based on Technology, the market is segmented into Immunoassays, Next-Generation Sequencing, Polymerase Chain Reaction, Mass Spectrometry, In-Situ Hybridization, Microarrays and Others. Based on Technique, the market is segmented into Genomics, Proteomics, Metabolomics and Epigenetics. Based on Application, the market is segmented into Research, Biomarker Discovery, Personalized Medicine, Clinical Application, Diagnostics, Prognostics, Screening and Treatment and Monitoring. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cancer Tumor Profiling Market

The rise in cancer cases significantly drives the growth of the global cancer tumor profiling market. This increase in cancer prevalence is influenced by several factors, including an aging population, population growth, and shifts in the incidence of various cancer-causing elements. As cancer remains a complex and pervasive disease with various underlying causes, the growing burden necessitates advanced profiling techniques to enhance diagnosis, treatment, and patient outcomes. The urgent need for tailored therapeutic approaches arises from this complex landscape, solidifying the importance of cancer tumor profiling in addressing the ongoing challenges posed by the escalating incidence of cancer worldwide.

Restraints in the Global Cancer Tumor Profiling Market

Challenges related to technical issues in sample collection and storage present significant obstacles to the growth of the global cancer tumor profiling market. While personalized medicine is rapidly evolving and transforming disease identification, classification, and treatment in healthcare, these advancements are hampered by inconsistent sample management processes. As this more tailored approach to treatment becomes integrated into standard clinical practices, its impact on oncology is undeniable. However, the risks associated with sample handling and storage could impede the progress and acceptance of these innovations, ultimately affecting the overall development of the cancer tumor profiling sector.

Market Trends of the Global Cancer Tumor Profiling Market

The Global Cancer Tumor Profiling market is witnessing a significant trend driven by the integration of omics data and advancements in liquid biopsy technologies, projected to exhibit the highest CAGR during the forecast period. This shift aligns with the rising prominence of personalized medicine, transforming disease diagnosis, classification, and treatment. As tailored therapies become a standard in clinical practice, particularly within oncology, the market is evolving to accommodate innovative diagnostic tools and targeted treatment approaches. The convergence of advanced analytics and molecular profiling is revolutionizing cancer care, fostering early detection and improved patient outcomes across the globe.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Cancer Tumor Profiling Market Size by Cancer type & CAGR (2025-2032)

• Market Overview
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Melanoma Cancer
• Other Cancer

Global Cancer Tumor Profiling Market Size by Biomarker type & CAGR (2025-2032)

• Market Overview
• Genomic Biomarker
• Protein Biomarker

Global Cancer Tumor Profiling Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Immunoassays
• Next-Generation Sequencing
• Polymerase Chain Reaction
• Mass Spectrometry
• In-Situ Hybridization
• Microarrays
• Others

Global Cancer Tumor Profiling Market Size by Technique & CAGR (2025-2032)

• Market Overview
• Genomics
• Proteomics
• Metabolomics
• Epigenetics

Global Cancer Tumor Profiling Market Size by Application & CAGR (2025-2032)

• Market Overview
• Research
• Biomarker Discovery
• Personalized Medicine
• Clinical Application
• Diagnostics
• Prognostics
• Screening
• Treatment and Monitoring

Global Cancer Tumor Profiling Market Size & CAGR (2025-2032)

• North America (Cancer type, Biomarker type, Technology, Technique, Application)
  • US
  • Canada
• Europe (Cancer type, Biomarker type, Technology, Technique, Application)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Cancer type, Biomarker type, Technology, Technique, Application)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Cancer type, Biomarker type, Technology, Technique, Application)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Cancer type, Biomarker type, Technology, Technique, Application)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Illumina, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NeoGenomics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Diagnostics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Foundation Medicine, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations